In the BioHarmony Drug Report Database

"Preview" Icon

Auranofin

Ridaura (auranofin) is a small molecule pharmaceutical. Auranofin was first approved as Ridaura on 1985-05-24. It is used to treat pemphigus, psoriatic arthritis, and rheumatoid arthritis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1.

 

Trade Name

 

Ridaura
 

Common Name

 

auranofin
 

ChEMBL ID

 

CHEMBL1366
 

Indication

 

pemphigus, psoriatic arthritis, rheumatoid arthritis
 

Drug Class

 

Image (chem structure or protein)

Auranofin structure rendering